Stevens Capital Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Stevens Capital Management’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-9,984	Closed	-$203K	–	1155
2017 Q3	$203K	Buy	+9,984	New	+$191K	0.01%	760
2016 Q3	–	Sell	-13,718	Closed	-$395K	–	1255
2016 Q2	$395K	Buy	+13,718	New	+$447K	0.02%	625
2014 Q2	–	Sell	-18,363	Closed	-$485K	–	1426
2014 Q1	$485K	Buy	18,363 +7,917	+76%	+$198K	0.01%	668
2013 Q4	$263K	Sell	10,446 -6,297	-38%	-$140K	0.01%	824
2013 Q3	$343K	Buy	+16,743	New	+$346K	0.01%	744

Other funds holding IPXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCW Group Los Angeles, California $13.3B AUM 34.44% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Stevens Capital Management's IPXL Position: Q4 2017 in Review

Stevens Capital Management sold out of Impax Laboratories, Inc. (IPXL) in Q4 2017, closing a stake of 9,984 shares — an estimated $203K sold.

Stevens Capital Management first reported a position in IPXL in Q3 2013 and held it in 5 quarters. The position peaked at $485K in Q1 2014. 200 funds tracked by Wall St. Rank hold IPXL as of Q4 2017.

Stevens Capital Management reported no remaining Impax Laboratories, Inc. position as of Q4 2017 after selling out during the quarter.
Stevens Capital Management sold 9,984 Impax Laboratories, Inc. shares in Q4 2017, an estimated $203K.
Stevens Capital Management first reported a position in Impax Laboratories, Inc. in Q3 2013 and held it in 5 quarters.
Stevens Capital Management's Impax Laboratories, Inc. position peaked at $485K in Q1 2014.
200 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2017.

Based on Stevens Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.